Table 3 SLN positivity, type of metastasis and recurrence stratified according to Breslow thickness of primary tumour, for patients subject to CLND

From: The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases

Breslow (mm)

Patient (%) ( n =385)

Positive patient (%)

Micrometastasis in SLN (as % of positive SLN)

Macrometastasis in SLN (as % of positive SLN)

Recurrence after CLND (%)

Unknown

2.6 (n=10)

10 (n=1)

100 (n=1)

0

100 (n=1)

L/i=1

<1

3.6 (n=14)

14.3 (n=2)

100 (n=2)

0

0

1–2

48.1 (n=185)

21.6 (n=40)

60 (n=24)

40 (n=16)

27.5 (n=11)

L/i=2 n=6 d=3

2–4

31.7 (n=122)

27 (n=33)

66.7 (n=22)

33.3 (n=11)

30.3 (n=11)

L/i=5 n=3 d=3

>4

14.0 (n=54)

44.4 (n=24)

54.2 (n=13)

45.8 (n=11)

50 (n=12)

L/i=1 n=2 d=9

  1. CLND=completion lymph node dissection; d=distant; L/I=local/intransit; n=nodal; SLN=sentinel lymph node. The seven patients who refused CLND are excluded from the total number of patients.
Back to article page